Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$6.53
-1.4%
$7.07
$4.62
$13.47
$408.92M0.21.19 million shs699,856 shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$6.20
+2.0%
$5.87
$4.95
$12.83
$442.93M0.92730,523 shs422,137 shs
Verastem, Inc. stock logo
VSTM
Verastem
$5.90
-2.0%
$6.58
$2.10
$9.10
$324.20M0.851.13 million shs2.63 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
+1.85%+1.38%-9.32%-9.56%-40.41%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
+1.16%+2.88%+7.99%+11.97%-18.72%
Verastem, Inc. stock logo
VSTM
Verastem
-19.19%-27.56%-18.98%+2.03%+52.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.5564 of 5 stars
3.01.00.04.01.51.71.3
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
2.2276 of 5 stars
0.03.00.00.02.20.83.1
Verastem, Inc. stock logo
VSTM
Verastem
3.0444 of 5 stars
4.50.00.00.03.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2.06
Hold$8.8735.78% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
0.00
N/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.63130.93% Upside

Current Analyst Ratings Breakdown

Latest SCTL, SAGE, SIGA, and VSTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $14.00
4/25/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/10/2025
Verastem, Inc. stock logo
VSTM
Verastem
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00
3/24/2025
Verastem, Inc. stock logo
VSTM
Verastem
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $14.00
3/24/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
3/21/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
3/11/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$5.00
(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$47.40M8.63N/AN/A$7.56 per share0.86
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$120.33M3.68$0.98 per share6.34$2.77 per share2.24
Verastem, Inc. stock logo
VSTM
Verastem
$10M32.42N/AN/A$2.27 per share2.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$68.07M$0.675.174.96N/A49.33%49.06%38.72%7/30/2025 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$87.37M-$3.20N/AN/AN/AN/A-332.73%-73.97%8/14/2025 (Estimated)

Latest SCTL, SAGE, SIGA, and VSTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Verastem, Inc. stock logo
VSTM
Verastem
-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A
5/8/2025Q1 2025
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
3/20/2025Q4 2024
Verastem, Inc. stock logo
VSTM
Verastem
-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A
3/11/2025Q4 2024
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A$0.63N/A$0.63N/A$81.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A

Latest SCTL, SAGE, SIGA, and VSTM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/8/2025
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
special$0.604/29/20254/29/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
7.42
7.42
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A
8.10
5.32
Verastem, Inc. stock logo
VSTM
Verastem
2.77
3.23
3.23

Institutional Ownership

CompanyInstitutional Ownership
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
55.40%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
1.54%
Verastem, Inc. stock logo
VSTM
Verastem
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million58.10 millionOptionable
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
4071.44 million70.31 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5054.95 million43.53 millionOptionable

Recent News About These Companies

Verastem, Inc. stock logo
Verastem, Inc. (NASDAQ:VSTM) Short Interest Update
Verastem Announces Promising Phase 1 Study Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$6.53 -0.09 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$7.04 +0.52 (+7.89%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

SIGA Technologies stock logo

SIGA Technologies NASDAQ:SIGA

$6.20 +0.12 (+1.97%)
Closing price 04:00 PM Eastern
Extended Trading
$6.20 +0.00 (+0.08%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Verastem stock logo

Verastem NASDAQ:VSTM

$5.90 -0.12 (-1.99%)
Closing price 04:00 PM Eastern
Extended Trading
$5.88 -0.03 (-0.42%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.